Title : Bortezomib inhibits proteasomal degradation of IκBα and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma.

Pub. Date : 2014 Feb

PMID : 23697845






5 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Therefore, a panel of ABC cell lines was used to examine the effect of bortezomib, a proteasome inhibitor which blocks degradation of IkappaBalpha and consequently inhibits NFkappaB activity. Bortezomib nuclear factor kappa B subunit 1 Homo sapiens
2 We next determined the status of the NFkappaB pathway following bortezomib treatment and found that there was accumulation of IkappaBalpha without affecting its phosphorylation status at an early time point. Bortezomib nuclear factor kappa B subunit 1 Homo sapiens
3 Electrophoretic mobility shift assay showed that bortezomib treatment inhibited constitutive nuclear NFkappaB in ABC cell lines. Bortezomib nuclear factor kappa B subunit 1 Homo sapiens
4 Furthermore, treatment of ABC cell lines with bortezomib for 48 h also down-regulated the expression of NFkappaB-regulated gene products, such as IkappaBalpha, Bcl-2, Bcl-Xl, XIAP and survivin, leading to apoptosis via the mitochondrial apoptotic pathway. Bortezomib nuclear factor kappa B subunit 1 Homo sapiens
5 Altogether, these results suggest that NFkappaB may be a potential target for therapeutic intervention in DLBCL using proteasomal inhibitors such as bortezomib. Bortezomib nuclear factor kappa B subunit 1 Homo sapiens